1. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)
- Author
-
Knapp, Martin, King, Derek, Romeo, Renée, Adams, Jessica, Baldwin, Ashley, Ballard, Clive, Banerjee, Sube, Barber, Robert, Bentham, Peter, Brown, Richard G, Burns, Alistair, Dening, Tom, Findlay, David, Holmes, Clive, Johnson, Tony, Jones, Robert, Katona, Cornelius, Lindesay, James, Macharouthu, Ajay, McKeith, Ian, McShane, Rupert, O'Brien, John T, Phillips, Patrick PJ, Sheehan, Bart, and Howard, Robert
- Subjects
Health Services and Systems ,Biomedical and Clinical Sciences ,Health Sciences ,Psychology ,Alzheimer's Disease ,Aging ,Neurodegenerative ,Neurosciences ,Clinical Trials and Supportive Activities ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Cost Effectiveness Research ,Acquired Cognitive Impairment ,Brain Disorders ,Dementia ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Neurological ,Activities of Daily Living ,Aged ,Aged ,80 and over ,Alzheimer Disease ,Cholinesterase Inhibitors ,Cognition ,Cost-Benefit Analysis ,Donepezil ,Double-Blind Method ,England ,Female ,Health Care Costs ,Humans ,Indans ,Memantine ,Piperidines ,Quality of Life ,Wales ,Alzheimer's disease ,donepezil ,memantine ,cost-effectiveness ,Clinical Sciences ,Cognitive Sciences ,Geriatrics ,Clinical sciences ,Health services and systems ,Clinical and health psychology - Abstract
ObjectiveMost investigations of pharmacotherapy for treating Alzheimer's disease focus on patients with mild-to-moderate symptoms, with little evidence to guide clinical decisions when symptoms become severe. We examined whether continuing donepezil, or commencing memantine, is cost-effective for community-dwelling, moderate-to-severe Alzheimer's disease patients.MethodsCost-effectiveness analysis was based on a 52-week, multicentre, double-blind, placebo-controlled, factorial clinical trial. A total of 295 community-dwelling patients with moderate/severe Alzheimer's disease, already treated with donepezil, were randomised to: (i) continue donepezil; (ii) discontinue donepezil; (iii) discontinue donepezil and start memantine; or (iv) continue donepezil and start memantine.ResultsContinuing donepezil for 52 weeks was more cost-effective than discontinuation, considering cognition, activities of daily living and health-related quality of life. Starting memantine was more cost-effective than donepezil discontinuation. Donepezil-memantine combined is not more cost-effective than donepezil alone.ConclusionsRobust evidence is now available to inform clinical decisions and commissioning strategies so as to improve patients' lives whilst making efficient use of available resources. Clinical guidelines for treating moderate/severe Alzheimer's disease, such as those issued by NICE in England and Wales, should be revisited. © 2016 The Authors. International Journal of Geriatric Psychiatry published by John Wiley & Sons Ltd.
- Published
- 2017